FINHUB Insights

GILD · Q1 FY26 · Mar 31, 2026

Gilead Sciences Q1 FY26: where the revenue came from and where it went

Gilead Sciences Q1 FY26: revenue $7B (+4% year over year). Net profit $2B. Largest cohort HIV Products Biktarvy $3.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 7, 2026 10-Q
Sankey diagram of Gilead Sciences's income statement for Q1 FY26: revenue of $7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$7B +4% year over year
Gross profit$5.5B 79% margin
Operating profit$2.6B 37% margin
Net profit$2B 29% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 7 100% +4%
HIV Products Biktarvy 3.4 49% +7%
Other 1.3 19%
Oncology Product 0.8 11%
Trodelvy 0.4 6% +37%
Yescarta 0.3 4% −14%
Liver Disease Products Sofosbuvir… 0.3 4% −18%
HIV Products Genvoya 0.3 4% −27%
Liver Disease Products Vemlidy 0.2 3% −6%
Cost of revenue−1.420%
Gross profit5.579% margin+2pp
SG&A−1.421%+2pp
Other−1.521%+0pp
Operating profit2.637% margin+4pp
Tax−0.6
Net profit229%+9pp
Filing on EDGAR More quarters of GILD

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters